In a retrospective multicenter study by Kelly et al. [80], patients with RA-ILD receiving RTX as their first biologic factor had longer three- (92%), five- (82%), and seven-year (80%) survival than those whose first biologic treatment was a TNF inhibitor (82%, 76%, and 64%, respectively). Here, TNF is linked to interstitial lung disease.